Invited Speaker



Update time:2024-03-06 17:18

Xiaoying Huang Professor,PHD. & MD., chief physician,  doctoral supervisor

Vice President of the First Affiliated Hospital of Wenzhou Medical University

Vice Chair of Stem Cell and Tissue Engineering Committee of Chinese Society of Biological Engineering

Standing Committee member of International Exchange Branch of China anti-Cancer Association

Vice president of Female Physician Branch of Zhejiang Medical Doctor Association

Vice chairman of Internal Medicine Branch of Zhejiang Medical Association

Deputy chairman of Respiratory Rehabilitation Committee of Zhejiang Rehabilitation Medicine Association

Vice leader of lung Interstitial and pulmonary Vascular Group of Zhejiang Medical Association

Zhejiang New Century 151 talents first level

Leading talents of Scientific and Technological innovation of "Ten Thousand People Plan" in Zhejiang Province

High-level innovative health talents of Zhejiang province

Young and middle-aged academic leaders of colleges and universities in Zhejiang province

Topic title: Engineered Exosomes Derived from Mesenchymal Stem Cells for Targeted Therapy of Pulmonary Arterial Hypertension


To investigate the engineering modification of exosomes secreted by mesenchymal stem cells (MSC) cultured under hypoxia conditions to improve their target in the treatment of pulmonary hypertension, and to evaluate the efficacy of engineered exosomes in the treatment of pulmonary hypertension through animal models and explore the related mechanism of miRNA-mediated MSC exosomes in the treatment of pulmonary hypertension.

Hypoxia can simulate the growth of MSC in bone marrow, which is beneficial to the proliferation and anti-aging of MSC in mouse bone marrow, thus it has high activity of MSC exosomes.

Hypoxic MSC exosomes can effectively inhibit the proliferation of isolated pulmonary artery muscle cells under the condition of hypoxia, it can also inhibit pulmonary hypertension and reduce right heart hypertrophy in hypoxic mice.

Hypoxic MSC exosomes modified by glucuronide can accurately treat pulmonary hypertension and regulate pulmonary vascular remodeling without obvious toxic and side effects on liver and kidney.

MiR-140-5p inhibits CTCF and promotes BMPR2 expression for improving pulmonary hypertension. MiR-140-5p may be an important mechanism for MSCs exosomes to improve pulmonary hypertension by regulating CTCF/BMPR2 pathway

Congress has ended
Important Dates
Conference Dates
March 29-31, 2024
Deadline for Submission of Abstract

December 31, 2023

Still open for submission

Notification of Abstract Acceptance

January 15, 2024

January 25, 2024